% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Seum:294339,
      author       = {T. Seum$^*$ and C. Frick$^*$ and R. Cardoso$^*$ and M.
                      Bhardwaj$^*$ and M. Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{P}otential of pre-diagnostic metabolomics for colorectal
                      cancer risk assessment or early detection.},
      journal      = {npj precision oncology},
      volume       = {8},
      number       = {1},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2024-02172},
      pages        = {244},
      year         = {2024},
      note         = {#EA:C070#LA:C070#},
      abstract     = {This systematic review investigates the efficacy of
                      metabolite biomarkers for risk assessment or early detection
                      of colorectal cancer (CRC) and its precursors, focusing on
                      pre-diagnostic biospecimens. Searches in PubMed, Web of
                      Science, and SCOPUS through December 2023 identified
                      relevant prospective studies. Relevant data were extracted,
                      and the risk of bias was assessed with the QUADAS-2 tool.
                      Among the 26 studies included, significant heterogeneity
                      existed for case numbers, metabolite identification, and
                      validation approaches. Thirteen studies evaluated individual
                      metabolites, mainly lipids, while eleven studies derived
                      metabolite panels, and two studies did both. Nine panels
                      were internally validated, resulting in an area under the
                      curve (AUC) ranging from 0.69 to 0.95 for CRC precursors and
                      0.72 to 1.0 for CRC. External validation was limited to one
                      panel (AUC = 0.72). Metabolite panels and lipid-based
                      biomarkers show promise for CRC risk assessment and early
                      detection but require standardization and extensive
                      validation for clinical use.},
      cin          = {C070 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39462072},
      doi          = {10.1038/s41698-024-00732-5},
      url          = {https://inrepo02.dkfz.de/record/294339},
}